1, 25(OH)2D3 inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes

Current Medicinal Chemistry

Volumn 20, Issue 33, 2013, Pages 4131-4141

  Guo, Jian ^a,c   Ma, Zhenhua ^a   Ma, Qingyong ^a   Wu, Zheng ^a   Fan, Ping ^a   Zhou, Xiaojie ^b   Chen, Lulu ^c   Zhou, Shuang ^d   Goltzman, David ^e   Miao, Dengshun ^c,e   Wu, Erxi ^d  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Shaanxi Food and Drug Administration   (China)

^c Laboratory of Reproductive Medicine   (China)

^d NORTH DAKOTA STATE UNIVERSITY   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

1 (OH)ase; 1,25(OH)2D3; Chronic inflammation; Coculture; Gene knockout; HCC; IL 6; P27kip1; STAT3 signaling; TNF

Indexed keywords

CALCITRIOL; CYCLIN DEPENDENT KINASE INHIBITOR 1B; INTERLEUKIN 6; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; GENOTYPE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KNOCKOUT GENE; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; LYMPHOCYTE; MOUSE; NONHUMAN; TUMOR GROWTH;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; APOPTOSIS; CALCITRIOL; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORYLATION; RECEPTORS, CALCITRIOL; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84887980891     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990248     Document Type: Article

References (38)

1. Llovet, J.M.; Burroughs, A.; Bruix, J. Hepatocellular carcinoma. Lancet, 2003, 362, 1907-1917.
2. McGlynn, K.A.; London, W.T. The global epidemiology of hepatocellular carcinoma: present and future. Clin. Liver Dis., 2011, 15, 223-243.
3. Lopez, P.M.; Villanueva, A.; Llovet, J.M. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol. Ther., 2006, 23, 1535-1547.
4. Portolani, N.; Coniglio, A.; Ghidoni, S.; Giovanelli, M.; Benetti, A.; Tiberio, G.A.; Giulini, S.M. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann. Surg., 2006, 243,229-235.
5. Kolligs, F.T.; Hoffmann, R.T.; Winkel, M.; Bruns, C.J.; Herrmann, K.; Jakobs, T.F.; Lamerz, R.; Trumm, C.; Zech, C.J.; Wilkowski, R.; Graeb, C. Diagnosis and multimodal therapy for hepatocellular carcinoma. Z. Gastroenterol., 2011, 48, 274-288.
6. Lin, W.W.; Karin, M.A. Cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest., 2007, 117,1175-1183.
7. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell, 2010, 140, 883-899.
8. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature, 2002, 420, 860-867.
9. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357, 539-545.
10. Tilg, H.; Wilmer, A.; Vogel, W.; Herold, M.; Nolchen, B.; Judmaier, G.; Huber, C. Serum levels of cytokines in chronic liver diseases. Gastroenterology, 1992, 103, 264-274.
11. Prieto, J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J. Hepatol., 2008, 48: 380-381.
12. Park, E.J.; Lee, J.H.; Yu, G.Y.; He, G.; Ali, S.R.; Holzer, R.G.; Osterreicher, C.H.; Takahashi, H.; Karin, M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell, 2009, 140, 197-208.
13. Wu, W.Y.; Li, J.; Wu, Z.S.; Zhang, C.L.; Meng, X.L. STAT3 activation in monocytes accelerates liver cancer progression. BMC. Cancer, 2011, 11, 506.
14. Giovannucci, E. Vitamin D and cancer incidence in the Harvard cohorts. Ann. Epidemiol., 2009, 19, 84-88.
15. Deeb, K.K.; Trump, D.L.; Johnson, C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer, 2007, 7, 684-700.
16. Gocek, E.; Studzinski, G.P. Vitamin D and differentiation in cancer. Crit. Rev. Clin. Lab. Sci., 2009, 46, 190-209.
17. Bhalla, A.K.; Amento, E.P.; Clemens, T.L.; Holick, M.F.; Krane, S.M. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab., 1983, 57, 1308-1310.
18. Vanoirbeek, E.; Krishnan, A.; Eelen, G.; Verlinden, L.; Bouillon, R.; Feldman, D.; Verstuyf, A. The anti-cancer and antiinflammatory actions of 1,25(OH)(2)D(3). Best. Pract. Res. Clin. Endocrinol. Metab., 2011, 25, 593-604.
19. Shah, S.; Islam, M.N.; Dakshanamurthy, S.; Rizvi, I.; Rao, M.; Herrell, R.; Zinser, G.; Valrance, M.; Aranda, A.; Moras, D.; Norman, A.; Welsh, J.; Byers, S.W. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol. Cell, 2006, 21, 799-809.
20. Nonn, L.; Peng, L.; Feldman, D.; Peehl, D.M. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res., 2006, 66, 4516-4524.
21. Hu, X.D.; Jiang, S.L.; Liu, C.H.; Hu, Y.Y.; Liu, C.; Sun, M.Y.; Chen, G.F.; Liu, P. Preventive effects of 1,25-(OH)2VD3 against ConA-induced mouse hepatitis through promoting vitamin D receptor gene expression. Acta. Pharmacol. Sin., 2010, 31,703-708.
22. Drocourt, L.; Ourlin, J.C.; Pascussi, J.M.; Maurel, P.; Vilarem, M.J. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem., 2002, 277, 25125-25132.
23. Yang, E.S.; Burnstein; K.L. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J. Biol. Chem., 2003, 278, 46862-46868.
24. Petta, S.; Camma, C.; Scazzone, C.; Tripodo, C.; Di Marco, V.; Bono, A.; Cabibi, D.; Licata, G.; Porcasi, R.; Marchesini, G.; Craxi, A. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology, 2010, 51,1158-1167.
25. Pappa, H.M.; Bern, E.; Kamin, D.; Grand, R.J. Vitamin D status in gastrointestinal and liver disease. Curr. Opin. Gastroenterol., 2008, 24, 176-183.
26. Malham, M.; Jorgensen, S.P.; Ott, P.; Agnholt, J.; Vilstrup, H.; Borre, M.; Dahlerup, J. F. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology. World J. Gastroenterol., 2011, 17, 922-925.
27. DeLuca, H.F. The kidney as an endocrine organ for the production of 1, 25-dihydroxyvitamin D3, a calcium-mobilizing hormone. N. Engl. J. Med., 1973, 289, 359-365.
28. Pourgholami, M.H.; Akhter, J.; Lu, Y.; Morris, D.L. In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. Cancer Lett., 2000, 151, 97-102.
29. Panda, D.K.; Miao, D.; Bolivar, I.; Li, J.; Huo, D.; Hendy, G. N.; Goltzman, D. Inactivation of the 25-hydroxyvitamin D 1alphahydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J. Biol. Chem., 2004, 279, 16754-16766.
30. Ben-Baruch, A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin. Cancer Biol., 2006, 16, 38-52.
31. Khan, Q.J.; Reddy, P.S.; Kimler, B.F.; Sharma, P.; Baxa, S.E.; O'Dea, A.P.; Klemp, J.R.; Fabian, C.J. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res. Treat., 2010, 119,111-118.
32. Smyth, M.J.; Cretney, E.; Kershaw, M.H.; Hayakawa, Y. Cytokines in cancer immunity and immunotherapy. Immunol. Rev., 2004, 202, 275-293.
33. He, G.; Karin, M. NF-kappaB and STAT3-key players in liver inflammation and cancer. Cell Res., 2011, 21, 159-168.
34. Abramovitch, S.; Dahan-Bachar, L.; Sharvit, E.; Weisman, Y.; Ben Tov, A.; Brazowski, E.; Reif, S. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut, 2011, 60, 1728-1737.
35. Kossatz, U.; Malek, N.P. p27: tumor suppressor and oncogene ...? Cell Res., 2007, 17, 832-833.
36. Sun, D.; Ren, H.; Oertel, M.; Sellers, R.S.; Zhu, L. Loss of p27Kip1 enhances tumor progression in chronic hepatocyte injuryinduced liver tumorigenesis with widely ranging effects on Cdk2 or Cdc2 activation. Carcinogenesis, 2007, 28, 1859-1866.
37. Sun, D.; Ren, H.; Oertel, M.; Sellers, R.S.; Shafritz, D.A.; Zhu, L. Inactivation of p27Kip1 promotes chemical mouse liver tumorigenesis in the resistant strain C57BL/6J. Mol. Carcinog., 2008, 47, 47-55.
38. Guo, J.; Ma, Q.; Zhou, X.; Shan, T.; Fan, P.; Miao, D. Inactivation of p27kip1 promotes carcinogens induced liver hepatocarcinogenesis through enhancing inflammatory cytokine secretion and STAT3 signaling activation. J. Cell. Physiol., 2013, Mar 4. doi: 10.1002/jcp.24357.